Esperion Therapeutics (ESPR)
(Real Time Quote from BATS)
$2.41 USD
+0.07 (2.99%)
Updated Jul 24, 2024 01:08 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
ESPR 2.41 +0.07(2.99%)
Will ESPR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ESPR
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
Other News for ESPR
Esperion to Participate in Upcoming BTIG Biotech Conference
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
Esperion announces 'Lipid Lurkers' digital first marketing campaign
Optimizing Cash Flow and Market Potential: A Buy Rating for Esperion
What You Missed On Wall Street This Morning